Your browser doesn't support javascript.
loading
Predictors and 5-Year Clinical Outcomes of Pacemaker After TAVR: Analysis From the PARTNER 2 SAPIEN 3 Registries.
Chen, Shmuel; Dizon, Jose M; Hahn, Rebecca T; Pibarot, Philippe; George, Isaac; Zhao, Yanglu; Blanke, Philipp; Kapadia, Samir; Babaliaros, Vasilis; Szeto, Wilson Y; Makkar, Raj; Thourani, Vinod H; Webb, John G; Mack, Michael J; Leon, Martin B; Kodali, Susheel; Nazif, Tamim M.
Afiliação
  • Chen S; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; Division of Cardiology, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, New York, USA.
  • Dizon JM; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; Division of Cardiology, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York, USA.
  • Hahn RT; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; Division of Cardiology, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York, USA.
  • Pibarot P; Department of Medicine, Laval University, Quebec, Quebec, Canada.
  • George I; Division of Cardiology, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York, USA.
  • Zhao Y; Edwards Lifesciences, Irvine, California, USA.
  • Blanke P; St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
  • Kapadia S; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Babaliaros V; Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Szeto WY; Division of Cardiovascular Surgery, Penn Medicine, University of Pennsylvania, Philadelphia, PA.
  • Makkar R; Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Thourani VH; Division of Cardiothoracic Surgery, Piedmont Heart Institute, Atlanta, Georgia, USA.
  • Webb JG; St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
  • Mack MJ; Baylor Scott & White Research Institute, Baylor Scott & White Health, Plano, Texas, USA.
  • Leon MB; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; Division of Cardiology, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York, USA.
  • Kodali S; Division of Cardiology, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York, USA.
  • Nazif TM; Division of Cardiology, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York, USA. Electronic address: Tmn31@cumc.columbia.edu.
JACC Cardiovasc Interv ; 17(11): 1325-1336, 2024 Jun 10.
Article em En | MEDLINE | ID: mdl-38866455
ABSTRACT

BACKGROUND:

Conduction disturbances requiring a permanent pacemaker (PPM) are a frequent complication of transcatheter aortic valve replacement (TAVR) with few reports of rates, predictors, and long-term clinical outcomes following implantation of the third-generation, balloon-expandable SAPIEN 3 (S3) transcatheter heart valve (THV).

OBJECTIVES:

The aim of this study was to investigate the rates, predictors, and long-term clinical outcomes of PPM implantation following TAVR with the S3 THV.

METHODS:

The current study included 857 patients in the PARTNER 2 S3 registries with intermediate and high surgical risk without prior PPM, and investigated predictors and 5-year clinical outcomes of new PPM implanted within 30 days of TAVR.

RESULTS:

Among 857 patients, 107 patients (12.5%) received a new PPM within 30 days after TAVR. By multivariable analysis, predictors of PPM included increased age, pre-existing right bundle branch block, larger THV size, greater THV oversizing, moderate or severe annulus calcification, and implantation depth >6 mm. At 5 years (median follow-up 1,682.0 days [min 2.0 days, max 2,283.0 days]), new PPM was not associated with increased rates of all-cause mortality (Adj HR 1.20; 95% CI 0.85-1.70; P = 0.30) or repeat hospitalization (Adj HR 1.22; 95% CI 0.67-2.21; P = 0.52). Patients with new PPM had a decline in left ventricular ejection fraction at 1 year that persisted at 5 years (55.1 ± 2.55 vs 60.4 ± 0.65; P = 0.02).

CONCLUSIONS:

PPM was required in 12.5% of patients without prior PPM who underwent TAVR with a SAPIEN 3 valve in the PARTNER 2 S3 registries and was not associated with worse clinical outcomes, including mortality, at 5 years. Modifiable factors that may reduce the PPM rate include bioprosthetic valve oversizing, prosthesis size, and implantation depth.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Valva Aórtica / Estenose da Valva Aórtica / Marca-Passo Artificial / Desenho de Prótese / Próteses Valvulares Cardíacas / Estimulação Cardíaca Artificial / Sistema de Registros / Substituição da Valva Aórtica Transcateter Limite: Aged / Aged80 / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: JACC Cardiovasc Interv Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Valva Aórtica / Estenose da Valva Aórtica / Marca-Passo Artificial / Desenho de Prótese / Próteses Valvulares Cardíacas / Estimulação Cardíaca Artificial / Sistema de Registros / Substituição da Valva Aórtica Transcateter Limite: Aged / Aged80 / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: JACC Cardiovasc Interv Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos